Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
US Stock Insider Trading | Heartflow disclosed two insider transactions on February 6
On February 6, 2026, Heartflow (HTFL) disclosed two insider trading transactions. Shareholder Bain Capital Life Sciences Investors, LLC, holding more than 10% of shares, sold 2,000,000 shares on February 5, 2026.
【Recent Insider Transactions】
| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD | | --- | --- | --- | --- | --- | --- | --- | --- | | February 6, 2026 | Shareholder with over 10% | Bain Capital Life Sciences Investors, LLC | February 4, 2026 | Sell | 2,000,000 | 28.05 | 56.1 million | | February 6, 2026 | Director | Cullivan Julie A | February 5, 2026 | Sell | 8,000 | 27.32 | 218,600 | | December 17, 2025 | Director | Lightcap Jeffrey C | December 16, 2025 | Buy | 40,000 | 26.34 | 1.0537 million | | November 12, 2025 | Director | Farquhar John C.M. | November 7, 2025 | Sell | 1,339 | 32.56 | 43,600 | | November 12, 2025 | Executive | Rogers Campbell | November 7, 2025 | Sell | 439 | 32.56 | 14,300 | | November 12, 2025 | Executive | Jones Marie L. | November 7, 2025 | Sell | 81 | 32.56 | 2,637.36 | | November 12, 2025 | Executive | Verghese Vikram | November 7, 2025 | Sell | 471 | 32.56 | 15,300 |
【Company Information】
Heartflow, Inc. was incorporated in 2007 under Delaware law. Heartflow pioneered the use of software and artificial intelligence to provide a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease, which is a leading cause of death worldwide. Their new platform leverages artificial intelligence and advanced computational fluid dynamics to create personalized 3D models of patients' hearts from a single coronary computed tomography angiography (CTA) scan, a specialized imaging type that provides detailed images of the heart arteries. Their Heartflow platform offers insights into blood flow, stenosis, plaque volume, and composition, overcoming the limitations of traditional non-invasive imaging tests that rely on indirect measurements of coronary artery disease, which can lead to higher false-negative and false-positive rates, as demonstrated by their precise trials.